Phase II study of cenersen, an antisense inhibitor of p53,...

Leukemia and Lymphoma 2012 / 02 Vol. 53; Iss. 2

Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia

Lanasa, Mark C., Davis, Patricia H., Datto, Michael, Li, Zhiguo, Gockerman, Jon P., Moore, Joseph O., DeCastro, Carlos M., Friedman, Daphne R., Diehl, Louis F., Rehder, Catherine, Cook, Harry, Daugher
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
53
Language:
english
Journal:
Leukemia & Lymphoma
DOI:
10.3109/10428194.2011.610012
Date:
February, 2012
File:
PDF, 223 KB
english, 2012
Conversion to is in progress
Conversion to is failed